GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year. The U.S. pharma giant expects adjusted EPS Of $ ...

Gardasil pause to China began this month Sales of Keytruda were over $7.8 billion in Q4, compared with analyst forecast of $7.4 billion Gardasil sales were $1.55 billion, compared with analyst ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

compared with analysts estimates of $9.03 a share. Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 billion, which has been pared back nearly 20% since the ...

The headwinds continue to play out despite Gardasil just last month nabbing an expanded approval in China to prevent certain HPV-related cancers and diseases in men ages 9 to 25, Merck pointed out ...

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company stated. Published first ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least ... expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 ...